Identification of targets for prostate cancer immunotherapy-Reference-Cited by-同舟云学术

Identification of targets for prostate cancer immunotherapy

Published:2019-01-06 Issue:5 Volume:79 Page:498-505
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Papanicolau‐Sengos Antonios¹,Yang Yuanquan²,Pabla Sarabjot¹,Lenzo Felicia L.¹,Kato Shumei³,Kurzrock Razelle³,DePietro Paul¹,Nesline Mary¹,Conroy Jeffrey¹²,Glenn Sean¹²,Chatta Gurkamal²,Morrison Carl¹²^ORCID

Affiliation:

1. OmniSeq, Inc.BuffaloNew York

2. Roswell Park Comprehensive Cancer CenterBuffaloNew York

3. Center for Personalized Cancer Therapy and Division of Hematology and OncologyUCSD Moores Cancer CenterLa JollaCalifornia

Funder

OmniSeq, Inc., Buffalo, New York

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23756

Reference59 articles.

1. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

2. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

3. Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

4. Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer

5. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pan-cancer analysis of immune checkpoint receptors and ligands in various cells in the tumor immune microenvironment;Aging;2024-08-07

2. Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis;npj Genomic Medicine;2023-01-20

3. Landscape of the intratumroal microenvironment in bladder cancer: Implications for prognosis and immunotherapy;Computational and Structural Biotechnology Journal;2023

4. Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives;Expert Review of Clinical Immunology;2022-09-26

5. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma;Frontiers in Immunology;2022-07-11